What is the recommended evaluation for hepatitis B infection?

Hepatitis B Assessment

All individuals with confirmed chronic hepatitis B infection require a comprehensive initial evaluation including serologic markers (HBsAg, HBeAg, anti-HBe, anti-HBc), quantitative HBV DNA, liver enzymes (ALT/AST), complete blood count, liver panel, and screening for coinfections (hepatitis C, D, and HIV in at-risk individuals). 1, 2

Initial Serologic Testing

• HBsAg confirmation: Chronic infection is confirmed by persistence of HBsAg for >6 months or absence of IgM anti-HBc in patients presenting de novo 1
• HBeAg and anti-HBe status: Determines phase of infection and level of viral replication 2
• Anti-HBc (total): Distinguishes chronic from acute infection 2, 1
• Quantitative HBV DNA: Essential for assessing viral replication and treatment decisions; levels ≥2,000 IU/mL indicate active disease 3, 4

Laboratory Assessment of Liver Disease

• ALT and AST levels: Monitor every 3-6 months initially; ALT >40 IU/L (traditional ULN) suggests active hepatitis 3, 4
• Complete blood count: Platelet count <120,000/mL suggests advanced fibrosis or cirrhosis 1
• Liver function panel: Assess for synthetic dysfunction (albumin, bilirubin, INR) 2
• Alpha-fetoprotein (AFP): Baseline measurement for future HCC surveillance 2

Assessment of Fibrosis and Cirrhosis

• Transient elastography (FibroScan): Non-invasive assessment of fibrosis; liver stiffness <9 kPa with normal ALT or <12 kPa with elevated ALT suggests absence of severe fibrosis 4
• Liver biopsy: Most useful when treatment indications are unclear; not mandatory if HBV DNA >20,000 IU/mL and ALT >2× ULN 3, 5
• Patients with platelets <120,000/mL or severe fibrosis: Require endoscopy to screen for varices 1

Screening for Hepatocellular Carcinoma

• Baseline abdominal ultrasound: Recommended for all HBsAg-positive persons ≥20 years old at initial presentation 1
• High-risk populations requiring HCC surveillance: Asian men >40 years, Asian women >50 years, all patients with cirrhosis, family history of HCC, Africans >20 years, and those with persistent ALT elevation and/or high HBV DNA 2
• Surveillance frequency: Ultrasound and AFP every 6-12 months for high-risk individuals 6

Coinfection Screening

• Hepatitis C virus (HCV): Test anti-HCV and HCV RNA if positive, especially in those with injection drug use or high-risk sexual behavior 2
• Hepatitis D virus (HDV): Test in patients with risk factors (injection drug use, endemic areas) 2
• HIV: Screen all patients with behavioral risk factors (men who have sex with men, injection drug users) 2
• Hepatitis A virus (HAV): Check anti-HAV antibody; vaccinate if seronegative (2 doses, 6-18 months apart) 2, 1

Clinical History and Physical Examination

Key historical elements to obtain:

• Family history: HBV infection, HCC, or cirrhosis in first-degree relatives increases risk 1, 2
• Alcohol consumption: Quantify intake; >40 g/day accelerates progression to cirrhosis 7
• Risk factors for coinfection: Injection drug use, multiple sexual partners, men who have sex with men 2
• Country of origin: Identify if from high-prevalence region (>2% HBsAg prevalence) 2
• Immunosuppressive therapy: Current or planned chemotherapy, biologics, or organ transplantation 2

Physical examination findings:

• Signs of chronic liver disease: Spider angiomata, palmar erythema, jaundice, ascites 2
• Hepatomegaly or splenomegaly suggesting portal hypertension 2
• Signs of decompensation: Ascites, peripheral edema, encephalopathy 3

Special Populations Requiring Additional Assessment

• Pregnant women: Check HBV DNA and ALT at 26-28 weeks gestation; if HBV DNA >10⁶ IU/mL, initiate antiviral therapy (tenofovir, telbivudine, or lamivudine) for remainder of pregnancy and 4 weeks postpartum 1
• Patients planning immunosuppressive therapy: Complete HBV serologic panel (HBsAg, anti-HBc, anti-HBs) before initiating therapy to assess reactivation risk 2
• Cirrhotic patients: Any detectable HBV DNA requires treatment regardless of ALT level 3, 4

Monitoring Frequency Based on Disease Phase

HBeAg-positive with normal ALT (immune tolerant):

• ALT every 3-6 months 5, 2
• HBeAg status every 6-12 months 5
• Consider liver biopsy if age >30 years or family history of HCC/cirrhosis 3

HBeAg-negative with normal ALT and HBV DNA <2,000 IU/mL (inactive carrier):

• ALT every 3 months for first year to confirm inactive state, then every 6-12 months 5, 2
• HBV DNA every 6-12 months 3

Active hepatitis (elevated ALT and HBV DNA ≥2,000 IU/mL):

• ALT and HBV DNA every 3 months if not on treatment 5
• Assess for treatment indications 3, 4

Vaccination of Contacts

• Household and sexual contacts: Screen for HBsAg, anti-HBc, and anti-HBs; vaccinate if seronegative 1, 2
• Healthcare workers with potential blood exposure: Vaccinate if not immune 1

Common Pitfalls to Avoid

• Single HBV DNA measurement: Viral load can fluctuate widely; serial monitoring is more informative than any single value 5
• Delaying HCC surveillance: Even patients <40 years can develop HCC; baseline ultrasound should be performed at initial presentation 1
• Missing occult hepatitis B: Isolated anti-HBc may indicate occult infection, especially in immunocompromised patients; check HBV DNA if ALT is elevated 1
• Inadequate monitoring of inactive carriers: Disease can reactivate after years of quiescence; lifelong monitoring is required 7